Downloads provided by UsageCountsPlease grant OpenAIRE to access and update your ORCID works.
This Research product is the result of merged Research products in OpenAIRE.
You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
This Research product is the result of merged Research products in OpenAIRE.
You have already added 0 works in your ORCID record related to the merged Research product.
You have already added 0 works in your ORCID record related to the merged Research product.
Antibody Characterization Report for Profilin-1
McDowell, Ian; Ayoubi, Riham; Ryan, Joel; Fotouhi, Maryam; Reintsch, Wolfgang; Durcan, Thomas M.; Brown, Claire M.; +2 Authors
McDowell, Ian; Ayoubi, Riham; Ryan, Joel; Fotouhi, Maryam; Reintsch, Wolfgang; Durcan, Thomas M.; Brown, Claire M.; McPherson, Peter S.; Laflamme, Carl;
Antibody Characterization Report for Profilin-1
Head-to-head comparison of available commercial antibodies against Profilin-1 by immunoblot (Western blot), immunoprecipitation and immunofluorescence. The workflow and data collected in this study was used to create an article published on F1000, DOI: 10.12688/f1000research.132249.1. Work reported in this report was supported in part by the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities: the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.
amyotrophic lateral sclerosis, antibody characterization, P07737, PFN1, Profilin-1, antibody validation, ALS-RAP
amyotrophic lateral sclerosis, antibody characterization, P07737, PFN1, Profilin-1, antibody validation, ALS-RAP
Laflamme, C., et al., Opinion: Independent third-party entities as a model for validation of commercial antibodies. N Biotechnol, 2021. 65: p. 1-8 DOI: 10.1016/j.nbt.2021.07.001.
Laflamme, C., et al., Implementation of an antibody characterization procedure and application to the major ALS/FTD disease gene C9ORF72. Elife, 2019. 8 DOI: 10.7554/eLife.48363.
Wang, M., et al., Version 4.0 of PaxDb: Protein abundance data, integrated across model organisms, tissues, and cell-lines. Proteomics, 2015. 15(18): p. 3163-8 DOI: 10.1002/pmic.201400441.
Cell, 2020. 180(2): p. 387-402 e16 DOI: 10.1016/j.cell.2019.12.023.
DepMap, Broad. 2019.
2021 DOI: https://doi.org/10.5281/zenodo.5717510.
Ayoubi, R., et al., Antibody screening by Immunoprecitation. 2021 DOI: https://doi.org/10.5281/zenodo.5717516.
Alshafie, W., P. McPherson, and C. Laflamme, Antibody screening by Immunofluorescence. 2021 DOI: https://doi.org/10.5281/zenodo.5717498.
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average views 162 downloads 105 citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average - 162views105downloads
citations
Citations provided by BIP!
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
Citations provided by BIP!popularityPopularity provided by BIP!
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
Popularity provided by BIP!influenceInfluence provided by BIP!
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
Influence provided by BIP!impulseImpulse provided by BIP!
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
Impulse provided by BIP!viewsViews provided by UsageCounts
Views provided by UsageCountsdownloadsDownloads provided by UsageCounts
Downloads provided by UsageCounts 0
Average
Average
Average
162
105
Head-to-head comparison of available commercial antibodies against Profilin-1 by immunoblot (Western blot), immunoprecipitation and immunofluorescence. The workflow and data collected in this study was used to create an article published on F1000, DOI: 10.12688/f1000research.132249.1. Work reported in this report was supported in part by the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities: the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.